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Abstract 
Background. Evidence to understand which gay and bisexual men (GBM) inject drugs 
remains scant, especially in the UK. We describe correlates of last-year injecting in UK 
GBM, and characterise subgroups of GBM who inject drugs by types of drugs used. 
Methods. Using data from the 2014 Gay Men’s Sex Survey, an opportunistic internet-based 
survey conducted of GBM living in the UK, we examined via logistic regression correlates 
with any injecting of six drugs (amphetamine/speed, crystal methamphetamine, heroin, 
mephedrone, GHB/GBL, and ketamine) in the last year. We estimated latent class models to 
understand underlying subgroups of injecting drug use among GBM reporting injecting drug 
use in the last year. 
Results. Injecting was most common in GBM who were of middle age, who were HIV 
seropositive, and who lived in London, and was significantly associated with sexual risk with 
multiple partners in the last year, whether steady or non-steady. Most GBM who engaged in 
injecting either injected crystal methamphetamine, mephedrone or both (class 1, chemsex, 
88.6% of injectors), whereas a smaller group had a focus on opiates (class 2, opiate, 7.9%). A 
small but identifiable subgroup (class 3, eclectic, 3.5%) engaged in injecting across the range 
of drugs examined. 
Conclusions. This is the first epidemiological analysis to describe subgroups of injecting, and 
to describe correlates of injecting drug use, in UK GBM. Implications for design of harm 
reduction services include a need to focus on injecting drug use beyond opiates, currently the 
focus of most harm reduction services. 
Keywords. injecting drug use; gay and bisexual men; latent class analysis; observational 
epidemiology 
  
1. Introduction 
 While drug use in gay and bisexual men (GBM) is consistently higher than in the 
general population (Lea et al., 2013; Melendez-Torres et al., 2016a), injecting drug use by gay 
and bisexual men (GBM) remains sparsely documented and poorly understood in the UK 
(Public Health England, 2016). This is despite increasing media attention from 2013 onwards 
(Kirby and Thornber-Dunwell, 2013; Shaw, 2017). Recent evidence from Australian GBM 
indicates a prevalence of drug injecting of 4.7% in the last six months, with lifetime 
prevalence of 10.6% (Bui et al., 2018), but epidemiological description of injecting drugs 
among UK GBM remains scant. While previous surveys document low levels of injection 
drug use among GBM in Europe (The EMIS Network, 2013), the emergence of ‘chemsex’, or 
the sexualised use of crystal methamphetamine, GHB, mephedrone and ketamine (Bourne et 
al., 2015a), has sparked concern about the current extent of injection drug use in this 
population. Injecting use of chemsex drugs may be a particularly salient feature of high-risk 
sexual practices, given the use of these drugs to enhance sexual performance and increase the 
number of partners in a coital session (Bourne et al., 2015b), and we have previously 
described the relationship between chemsex drug use before sex and sexual risk at the level of 
the sexual encounter (Melendez-Torres et al., 2016b). Major cross-sectional surveys of drug 
use by GBM have not been able to recruit enough GBM who inject drugs for comparison 
(Sewell et al., 2017). Data from the Unlinked and Anonymous Monitoring survey of people 
who inject drugs compared GBM and non-GBM among men who inject drugs and found that 
GBM were more likely to have recently begun injecting and to engage in high-risk sexual 
practices; however, this survey was unable to describe patterns within GBM who inject drugs 
(Glass et al., 2017). Not all injecting drug use may be related to sex, and different profiles of 
injecting drug use may exist among GBM. We present an observational epidemiological study 
based on cross-sectional survey data from a large number of GBM across the UK in which we 
describe demographic and socio-sexual correlates of drug injecting and characterise 
subgroups of GBM injectors by types of drugs used. 
2. Methods 
We used data from the Gay Men’s Sex Survey, a convenience sample survey of GBM 
living in the UK, and the longest-running community-based survey of GBM in the UK. GBM 
were recruited to an internet-based survey in late summer 2014 via dating websites, Facebook 
adverts and geosocial networking apps. Because of the recruitment methods used, a response 
rate is not available. We included in this analysis GBM over the age of 16 who identified as 
gay, bisexual or with another non-heterosexual identity; that is, men who described being 
sexually attracted to men. 
2.1. Correlates with last-year injecting 
Because injecting was relatively rare in this sample, we examined any injecting in the 
last year of any of six drugs (amphetamine/speed, crystal methamphetamine, heroin, 
mephedrone, GHB/GBL, and ketamine) as our binary dependent variable. We tested a set of 
bivariate logistic regression models, with independent variables including age group, region 
of residence, academic qualifications, full-time employment, HIV testing history, gay identity 
(defined as ‘gay’ or ‘bisexual and other non-heterosexual’), and number of steady and non-
steady partners and condom-unprotected anal intercourse (cUAI) in the last year. For both 
steady and non-steady partners, we constructed variables relating to both the quantity of 
partners and the sexual risk behaviours associated with each of those partnerships. This led to 
a four-category variable for non-steady partners: respondents reported one or more non-steady 
partners, but with no cUAI in any of those partnerships; respondents reported one non-steady 
partner with no cUAI in that partnership; respondents reported one non-steady partner with 
cUAI in that partnership; and respondents reported two or more non-steady partners with 
cUAI in two or more partnerships. Of note is that respondents could report both steady and 
non-steady partners in the last year. We constructed a similar variable for steady partners. 
Independent variables were chosen on the basis of our prior work in understanding drug use 
patterns in GBM (Melendez-Torres et al., 2016a), and account for both demographic 
characteristics and behavioural risk factors. We then included significant predictors in a 
multivariable model. Because of the sparseness of our outcome, we confirmed the robustness 
of the multivariable analysis using a logistic regression model with penalised likelihood 
estimation, which was developed for use with rare outcomes. A significance level of p<0.05 
was used in all analyses. 
2.2. Latent class models 
We then estimated latent class models to examine potential subgroups of GBM who 
inject drugs by type of drug injected in the last year. We estimated models using full 
information maximum likelihood and weakly informative data-driven prior distributions to 
stabilise estimation. We tested these models with a successive number of classes, starting with 
two classes, until we reached an optimal solution on scaled relative entropy (roughly 
equivalent to R2 in a linear regression). We then interpreted the latent classes by examining 
the conditional probabilities of injecting different drugs within each class (i.e. how likely 
those in each latent class were to have injected each of the six drugs). All models were 
implemented in Stata v 14 (Statacorp, College Station, TX). 
3. Results 
Of the 16,464 GBM in our sample, 303 (1.81%) reported injecting in the last year. An 
additional 176 GBM (1.05%) reported ever injecting, but more than 12 months ago. In total, 
16,288 GBM (97.14%) report never injecting drugs. More than half of the sample (52.97%) 
was between the ages of 30 and 59, and nearly a quarter (24.10%) of the sample was from the 
London integrated region.  More than two-third (67.20%) reported that their last HIV test was 
negative (see Table 1). 
3.1. Correlates with last-year injecting 
Based on bivariate regressions, GBM between the ages of 30 and 59 were most likely 
to have injected drugs and those between the ages of 16 and 19 were least likely to inject (see 
Table 1). GBM reporting injecting drug use were more likely to live in London than other 
regions of the UK. Compared to GBM who last tested negative for HIV, GBM who tested 
positive were more likely to have injected, and GBM who had never received a test result 
were less likely to have injected. GBM who did identified as gay were more likely to have 
injected than those who did not. Neither education nor full-time employment was 
significantly associated with last-year injecting. 
Sexual history in the last year was associated with last-year injecting. Compared to 
GBM who had one or more steady partners but had not engaged in cUAI, GBM with no 
steady partners or one or more steady partners with cUAI were more likely to have injected in 
the last year. Associations with non-steady partners showed a similar trend but GBM with 
non-steady partners and no cUAI were no more or less likely to inject than those with no non-
steady partners. 
Multivariable models presented a similar picture, though sexual identity was no longer 
a significant correlate of last-year injecting and not all UK regions were significantly different 
from London in last-year injecting. Multivariable model results were similar with penalised 
quasi-likelihood estimation. 
3.2. Latent class models 
We tested a two-class, three-class and four-class solution and chose a three-class 
solution (see Table 2) because it had the optimal balance between fit to the data and 
complexity based on relative squared entropy. 
The first class, chemsex injecting drug use, was defined by use of mostly crystal 
methamphetamine and mephedrone, as these were the two highest conditional probabilities in 
the class. That is, this class was composed mostly of GBM who inject drugs who used either 
or both of these drugs but little use of other drugs. Use of ketamine in this class was about the 
same in the sample of GBM who inject drugs as a whole. In contrast, use of heroin was 
almost non-existent in this class. This class composed 88.6% of GBM reporting last-year 
injecting drug use. 
The second class, opiate injecting drug use, was characterised by low probabilities 
across all drugs, though heroin was most injected in this class and notably crystal 
methamphetamine, mephedrone and ketamine injecting were much rarer in this class than in 
the sample of GBM who inject drugs as a whole. This class composed 7.9% of GBM 
reporting last-year injecting drug use. 
Finally, the third class, eclectic injecting drug use, was characterised by high injecting 
across all drugs, but most notably across amphetamine, crystal methamphetamine, 
mephedrone and ketamine. That is, this class was composed of GBM most of whom injected 
all four of these drugs in the last year. GHB injecting was also more than eight times as likely 
in this class as in the sample of GBM who inject drugs as a whole. Only 3.5% of GBM 
reporting last-year injecting drug use belonged to this class. 
4. Discussion 
This is the first epidemiological analysis describing subgroups of injectors among 
GBM living in the UK, and the first to describe correlates of injecting drug use in UK GBM. 
We were able to describe subgroups within the sample of GBM reporting injecting drugs in 
the last year. Most GBM who engaged in injecting either injected crystal methamphetamine, 
mephedrone or both, whereas a smaller group described engaging in generic injecting 
practices with a focus on opiates. A small but identifiable subgroup engaged in injecting 
across the range of drugs examined. As compared to the most recent evidence in injecting 
drug use on GBM in Australia (Bui et al., 2018), our study showed lower prevalence of 
injecting (1.81% in the last year in this analysis vs 4.7% in the last six months in their study) 
and no relationship between employment and injecting drug use. While we did not find a 
significant relationship in bivariate models, they found that unemployment was predictive of 
higher prevalence of injecting drug use. Like their study, we found that injecting drug use was 
positively associated with middle age, known HIV seropositive status and more sexual 
partners in the recent past. Moreover, as compared to estimates of population prevalence of 
injecting in the United Kingdom at 3.0 per 1,000 population (European Monitoring Centre for 
Drugs and Drug Addiction, 2017), our study showed a much higher prevalence. 
A key implication for design of harm reduction services is that the vast majority of 
GBM who reported injecting drug use were injecting drugs associated with chemsex, and not 
opiates, for whom most harm reduction services in the UK are designed (Bourne et al., 
2015a). Harm reduction services for a variety of injecting behaviours, that is to say, for 
chemsex drugs in which injecting use is generally related to sexual behaviour and not just for 
opiates, should be available to all GBM. In addition, it is important to understand the small 
but potentially very high-risk group of GBM who reported eclectic injecting drug use (class 
3), though our data do not permit an understanding of safe injecting practices and contexts. 
4.1. Limitations 
We drew on a community-based sample of GBM known to be at higher sexual risk 
(Dodds et al., 2006; Prah et al., 2016). Because data collection was internet-based, we under-
represent GBM with less structured access to internet services. In addition, we only asked 
about injection of six different types of drugs. The cross-sectional nature of our data mean 
that temporality (and thus causality) cannot be established between correlates and drug use. 
Future research should seek to understand correlates of membership in different types of 
injection drug use to better inform intervention targeting. 
4.2. Conclusions 
Evidence to support an informed response to injecting drug use in GBM remains 
scant. However, these analyses provide preliminary epidemiologic intelligence to support 
service design and provision to minimise the harms accruing from injecting drug use among 
gay men and other GBM. 
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Table 1. Correlates with last-year injecting in GBM. *p<0.05, **p<0.01, ***p<0.001 
 
Variable 
Distribution in 
the analysis 
sample (%) 
n/N (%) reporting 
last year injecting 
OR (95% CI) adjusted OR (95% CI) 
Age range 
16-19 7.50 3/1,254 (0.24) 0.23* (0.07, 0.72) 0.42 (0.13, 1.36) 
20-29 35.23 62/5,887 (1.05) Ref Ref 
30-59 52.97 229/8,685 (2.64) 2.54*** (1.92, 3.38) 1.56** (1.13, 2.16) 
60+ 5.30 9/885 (1.02) 0.97 (0.48, 1.95) 0.98 (0.47, 2.06) 
Highest qualification 
No secondary qualifications, O-levels, GCSE 17.66 43/2,903 (1.48) Ref   
A-levels 33.76 91/5,550 (1.64) 1.11 (0.77, 1.60)   
University degree 48.59 156/7,988 (1.95) 1.32 (0.94, 1.86)   
Employment 
Employed full-time 58.74 177/9,733 (1.82) Ref   
Not employed full-time 41.26 117/6,838 (1.71) 0.94 (0.74, 1.19)   
Where respondent lives 
London integrated region and centre 24.10 128/3,950 (3.24) Ref Ref 
North of England 23.67 51/3,880 (1.31) 0.40*** (0.29, 0.55) 0.65* (0.45, 0.93) 
Midlands and East of England 21.14 50/3,465 (1.44) 0.44*** (0.31, 0.61) 0.71 (0.49, 1.03) 
South of England 22.32 47/3,658 (1.28) 0.39*** (0.28, 0.54) 0.50*** (0.34, 0.73) 
Devolved nations 8.77 21/1,438 (1.46) 0.44*** (0.28, 0.70) 0.69 (0.41, 1.17) 
HIV testing history 
Last test negative 67.20 123/11,233 (1.09) Ref Ref 
Never received a test result 23.98 14/4,009 (0.35) 0.32*** (0.18, 0.55) 0.68 (0.38, 1.20) 
Test positive 8.82 166/1,474 (11.26) 11.46*** (9.02, 11.57) 5.54*** (4.18, 7.36) 
Sexual identity 
Gay 84.41 272/13,991 (1.94) Ref Ref 
Other 15.59 25/2,585 (0.97) 0.49*** (0.33, 0.74) 0.71 (0.44, 1.12) 
Steady male partners for cUAI in the last year 
Steady partner(s), no cUAI 16.79 20/2,541 (0.79) Ref Ref 
No steady partner 40.89 127/6,189 (2.05) 2.64*** (1.64, 4.24) 1.29 (0.78, 2.14) 
1 steady cUAI partner 34.53 80/5,226 (1.53) 1.96** (1.20, 3.21) 1.51** (1.42, 4.53) 
2+ steady cUAI partners 7.78 58/1,178 (4.92) 6.53*** (3.91, 10.90) 2.22** (5.27, 12.67) 
Non-steady male partners for cUAI in the last year 
Non-steady partner(s), no cUAI 38.37 26/5,825 (0.45) Ref Ref 
No non-steady partners 26.86 21/4,078 (0.51) 1.15 (0.65, 2.05) 1.22 (0.67, 2.22) 
1 non-steady cUAI partner 13.10 22/1,989 (1.11) 2.49** (1.41, 4.41) 2.54** (1.42, 4.53) 
2+ non-steady cUAI partners 21.67 215/3,290 (6.53) 15.59*** (10.36, 23.48) 8.17*** (5.27, 12.67) 
 
  
Table 2. Latent classes of injecting drug use in GBM. 
 
Drug % (n) Class 1 (%) Class 2 (%) Class 3 (%) 
Amphetamine 5.94 (18) 2.43 15.97 71.90 
Crystal meth 60.07 (182) 63.54 11.79 81.67 
Heroin 3.63 (11) 0.002 37.35 18.82 
Mephedrone 60.40 (183) 63.34 10.28 99.67 
GHB/GBL 1.98 (6) 1.21 4.20 16.43 
Ketamine 11.88 (36) 9.49 0.06 98.92 
 
